ChemPartner and Trianni Announce Partnering Agreement
SAN FRANCISCO, Aug. 2, 2016 /PRNewswire/ — Trianni, Inc. (“TRIANNI”) and ChemPartner, a leading science-driven, technologically advanced, high-quality preclinical research partner, today announced an agreement designed to facilitate third-party access to The Trianni Technology Platform.
“We are happy to welcome ChemPartner as a partner,” said Dr. Matthias Wabl, Ph.D., Chairman and CEO of TRIANNI. “Because our platform has the full repertoire of human immunoglobulin variable regions which undergo robust affinity maturation upon immunization, we expect it will greatly contribute to ChemPartner clients’ discovery pipelines.”
“We are delighted to now be able to add Trianni’s technology to our growing repertoire of antibody drug discovery services,” said Michael Hui, Chairman and CEO, of ChemPartner. “As part of our on-going initiative to offer a fully-enabled spectrum of services in this space, we believe the Trianni Mouse will provide our global clients with more choices and better odds of success in their efforts to develop impactful therapies.”
About Trianni, Inc.
Trianni is a privately held organization formed in 2010 with a mission to leverage recent advances in DNA synthesis and genomic modification technology toward development of an optimized therapeutic antibody discovery platform – The Trianni Mouse. The company is headquartered in the San Francisco Bay Area (CA, USA). For more information, please visit www.trianni.com.
ChemPartner is the service division of the ShangPharma group. ChemPartner is a leading research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. The company offers a broad range of integrated services across the drug discovery and development process to pharmaceutical and biotechnology companies around the globe. ChemPartner’s services consist of discovery biologics, discovery chemistry, discovery biology and preclinical development, pharmaceutical development, small molecule and biologics manufacturing services. To learn more visit: www.0914rencai.com
Contacts – TRIANNI
Director of Marketing
1.415.231.0256 [o] 1.866.674.9314
Robert A. Drakas
Executive Director of Business Development, East Coast USA
Sarah E Lively
Executive Director, Head of South San Francisco Site
Executive Director of Business Development, Europe
Executive Director of Business Development, Japan